These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27108802)

  • 1. Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England.
    van Hoek AJ; Campbell H; Amirthalingam G; Andrews N; Miller E
    J Infect; 2016 Jul; 73(1):28-37. PubMed ID: 27108802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies.
    Lugnér AK; van der Maas N; van Boven M; Mooi FR; de Melker HE
    Vaccine; 2013 Nov; 31(46):5392-7. PubMed ID: 24075918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?
    Van Bellinghen LA; Dimitroff A; Haberl M; Li X; Manton A; Moeremans K; Demarteau N
    Hum Vaccin Immunother; 2018; 14(9):2263-2273. PubMed ID: 29771574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis.
    Sandmann F; Jit M; Andrews N; Buckley HL; Campbell H; Ribeiro S; Sile B; Stowe J; Tessier E; Ramsay M; Amirthalingam G; Choi YH
    Vaccine; 2021 Jul; 39(32):4500-4509. PubMed ID: 34183204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
    Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
    Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of maternal pertussis vaccination in England: an observational study.
    Amirthalingam G; Andrews N; Campbell H; Ribeiro S; Kara E; Donegan K; Fry NK; Miller E; Ramsay M
    Lancet; 2014 Oct; 384(9953):1521-8. PubMed ID: 25037990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit of the introduction of new strategies for vaccination against pertussis in Spain: cocooning and pregnant vaccination strategies.
    Fernández-Cano MI; Armadans Gil L; Campins Martí M
    Vaccine; 2015 May; 33(19):2213-2220. PubMed ID: 25825331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
    Hoshi SL; Seposo X; Okubo I; Kondo M
    Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertussis immunization of adolescents in the United States: an economic evaluation.
    Caro JJ; Getsios D; El-Hadi W; Payne K; O'Brien JA
    Pediatr Infect Dis J; 2005 May; 24(5 Suppl):S75-82. PubMed ID: 15876932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands.
    Westra TA; de Vries R; Tamminga JJ; Sauboin CJ; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1479-95. PubMed ID: 20728761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adult pertussis vaccination in Germany.
    Lee GM; Riffelmann M; Wirsing von Konig CH
    Vaccine; 2008 Jul; 26(29-30):3673-9. PubMed ID: 18538901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants?
    van der Maas NA; Mooi FR; de Greeff SC; Berbers GA; Spaendonck MA; de Melker HE
    Vaccine; 2013 Sep; 31(41):4541-7. PubMed ID: 23933365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.
    Tormans G; Van Doorslaer E; van Damme P; Clara R; Schmitt HJ
    Eur J Pediatr; 1998 May; 157(5):395-401. PubMed ID: 9625337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.
    Scuffham PA; McIntyre PB
    Vaccine; 2004 Jul; 22(21-22):2953-64. PubMed ID: 15246632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the US.
    Curran D; Terlinden A; Poirrier JE; Masseria C; Krishnarajah G
    Pediatr Infect Dis J; 2016 May; 35(5):542-7. PubMed ID: 26835971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of next-generation vaccines: The case of pertussis.
    Fitzpatrick MC; Wenzel NS; Scarpino SV; Althouse BM; Atkins KE; Galvani AP; Townsend JP
    Vaccine; 2016 Jun; 34(29):3405-11. PubMed ID: 27087151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.
    Giorgakoudi K; O'Sullivan C; Heath PT; Ladhani S; Lamagni T; Ramsay M; Al-Janabi H; Trotter C
    Vaccine; 2018 Nov; 36(46):7033-7042. PubMed ID: 30293765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of pertussis vaccination in adults.
    Lee GM; Murphy TV; Lett S; Cortese MM; Kretsinger K; Schauer S; Lieu TA
    Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.
    Itatani T; Shimizu S; Iwasa M; Ohkusa Y; Hayakawa K
    Vaccine; 2013 Jun; 31(27):2891-7. PubMed ID: 23570987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.